Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
Authors:
- The Diabetes ControlTCThe Diabetes Control
- Complications Trial (Dcct)/Epidemiology Of Diabetes InterventionsCIComplications Trial (Dcct)/Epidemiology Of Diabetes Interventions
- Complications (EDIC) Study Research GroupCGComplications (EDIC) Study Research Group
Open Access
- 12 July 2016
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (8) , 1378-1383
Abstract
OBJECTIVE: Historically, mortality in type 1 diabetes has exceeded that in the general population. We compared mortality in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study cohort to that of the current general U.S. population. RESEARCH DESIGN AND METHODS: The DCCT (1983–1993) compared intensive versus conventional therapy, with HbA1c levels of ∼7 vs. 9%, respectively, over an average of 6.5 years of treatment. EDIC is the observational follow-up study of the DCCT (1994 to the present). Vital status was ascertained for 97.5% of the original DCCT cohort (n = 1,441) after a mean of 27 years follow-up. Expected mortality during DCCT/EDIC was estimated using the current age-, sex-, and race-specific risks in the general U.S. population, and the observed versus expected mortality compared using standardized mortality ratios (SMRs) and Poisson regression models. RESULTS: Mortality in the DCCT intensive therapy group was nonsignificantly lower than that in the general U.S. population (SMR = 0.88 [95% CI 0.67, 1.16]), whereas mortality in the DCCT conventional therapy group was significantly greater than that in the general population (SMR = 1.31 [95% CI 1.05, 1.65]). The SMR increased with increasing mean HbA1c, and above an HbA1c of 9%, the rate of increase in SMR among females was greater than that among males. CONCLUSIONS: Overall mortality in the combined DCCT/EDIC cohort was similar to that of the general population but was higher in the DCCT conventional therapy group. Mortality increased significantly with increasing mean HbA1c, more so among females than males, especially for HbA1c >9%.Keywords
Funding Information
- Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK094176, U01 DK094157)
This publication has 28 references indexed in Scilit:
- Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage StudyPLOS Medicine, 2012
- Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort studyBMJ, 2011
- All-Cause Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 DiabetesDiabetes Care, 2010
- In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications StudyDiabetologia, 2010
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009
- The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 DiabetesDiabetes, 2009
- Association between Glycosylated Hemoglobin Level and Cardiovascular and All-Cause Mortality in Type 1 DiabetesAmerican Journal of Epidemiology, 2007
- The British Diabetic Association Cohort Study, I: all‐cause mortality in patients with insulin‐treated diabetes mellitusDiabetic Medicine, 1999
- Trends in Mortality of Childhood‐onset Insulin‐dependent Diabetes Mellitus in Leicestershire: 1940–1991Diabetic Medicine, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993